Literature DB >> 20066537

Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation.

Efstathios K Iliodromitis1, Ioanna Andreadou, Eftihios Prokovas, Anastasia Zoga, Dimitrios Farmakis, Theano Fotopoulou, Konstantinos Ioannidis, Ioannis A Paraskevaidis, Dimitrios Th Kremastinos.   

Abstract

Postconditioning (POC) reduces lethal reperfusion injury under normal conditions, but its effectiveness under certain pathological states is in dispute. In the present study, we sought to determine the effect of chronic simvastatin treatment in hyperlipidemic animals with or without POC. Anesthetized rabbits were randomized into eight groups, as follows, and were subjected to 30-min myocardial ischemia followed by 3-h reperfusion. Normally fed animals: a Control group with no additional intervention, a Sim group treated with simvastatin for 3 weeks at a dose of 3 mg kg(-1), a POC group subjected to POC with eight cycles of 30-s ischemia/reperfusion, a Sim-POC group treated with simvastatin, and POC. Cholesterol fed (6 weeks) animals: a Chol group with no additional interventions, a Chol-Sim group treated with simvastatin for 3 weeks, a Chol-POC group subjected to POC, and a Chol-Sim-POC group treated with simvastatin and POC. Infarct size and plasma levels of malondialdehyde (MDA), nitrotyrosine (NT), NOx, total cholesterol, and LDL were evaluated. In a second series of experiments, heart tissue samples were taken for MDA, NT, and NOx assessment. Infarct size, circulating MDA, NT, NOx and cardiac MDA, NT, and NOx levels declined in POC and all Sim groups compared with Control, Chol, and Chol-POC (p < 0.05). Simvastatin also reduced total cholesterol and LDL plasma levels. In conclusion, a 3-week simvastatin treatment limits the infarct size and attenuates the oxidative and nitrosative stress both in normo- and in hyper-cholesterolemic rabbits subjected to ischemia-reperfusion irrespective of the presence of POC, while POC is effective only in normocholesterolemic animals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066537     DOI: 10.1007/s00395-009-0078-3

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  15 in total

1.  Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.

Authors:  Silvio Antoniak; Mauricio Rojas; Denise Spring; Tara A Bullard; Edward D Verrier; Burns C Blaxall; Nigel Mackman; Rafal Pawlinski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-19       Impact factor: 8.311

Review 2.  Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Antigone Lazou; Anikó Görbe; Zoltán Giricz; Rainer Schulz; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

Review 3.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

4.  Hypercholesterolemia increases mitochondrial oxidative stress and enhances the MPT response in the porcine myocardium: beneficial effects of chronic exercise.

Authors:  Kyle S McCommis; Allison M McGee; M Harold Laughlin; Douglas K Bowles; Christopher P Baines
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-24       Impact factor: 3.619

Review 5.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

6.  Post-ischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation.

Authors:  Claudia Penna; Maria-Giulia Perrelli; Francesca Tullio; Francesca Moro; Maria Laura Parisella; Annalisa Merlino; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2011-05-05       Impact factor: 3.657

Review 7.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

8.  Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction.

Authors:  Colin E Murdoch; Sara P Alom-Ruiz; Minshu Wang; Min Zhang; Simon Walker; Bin Yu; Alison Brewer; Ajay M Shah
Journal:  Basic Res Cardiol       Date:  2011-04-29       Impact factor: 17.165

9.  Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction.

Authors:  Xian-Liang Tang; Santosh K Sanganalmath; Hiroshi Sato; Qiuli Bi; Greg Hunt; Robert J Vincent; Yong Peng; Gregg Shirk; Buddhadeb Dawn; Roberto Bolli
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

10.  Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling.

Authors:  Javier Inserte; Victor Hernando; Úrsula Vilardosa; Elena Abad; Marcos Poncelas-Nozal; David Garcia-Dorado
Journal:  J Am Heart Assoc       Date:  2013-01-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.